Bouvel Investment Partners LLC Increases Holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Bouvel Investment Partners LLC raised its stake in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 2.9% in the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 14,356 shares of the medical equipment provider’s stock after purchasing an additional 406 shares during the period. Intuitive Surgical accounts for about 2.7% of Bouvel Investment Partners LLC’s investment portfolio, making the stock its 10th biggest holding. Bouvel Investment Partners LLC’s holdings in Intuitive Surgical were worth $7,493,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. Hazlett Burt & Watson Inc. increased its holdings in Intuitive Surgical by 5.8% in the 3rd quarter. Hazlett Burt & Watson Inc. now owns 362 shares of the medical equipment provider’s stock worth $177,000 after acquiring an additional 20 shares in the last quarter. Mitchell Mcleod Pugh & Williams Inc. boosted its position in shares of Intuitive Surgical by 4.1% in the third quarter. Mitchell Mcleod Pugh & Williams Inc. now owns 503 shares of the medical equipment provider’s stock worth $247,000 after purchasing an additional 20 shares during the period. Fragasso Financial Advisors Inc increased its stake in shares of Intuitive Surgical by 3.0% in the fourth quarter. Fragasso Financial Advisors Inc now owns 687 shares of the medical equipment provider’s stock worth $359,000 after purchasing an additional 20 shares in the last quarter. Ullmann Wealth Partners Group LLC raised its position in shares of Intuitive Surgical by 1.6% during the 3rd quarter. Ullmann Wealth Partners Group LLC now owns 1,329 shares of the medical equipment provider’s stock valued at $653,000 after purchasing an additional 21 shares during the period. Finally, Meeder Advisory Services Inc. lifted its stake in shares of Intuitive Surgical by 0.3% during the 3rd quarter. Meeder Advisory Services Inc. now owns 7,386 shares of the medical equipment provider’s stock valued at $3,629,000 after buying an additional 22 shares in the last quarter. Hedge funds and other institutional investors own 83.64% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the company. Royal Bank of Canada increased their price target on Intuitive Surgical from $525.00 to $555.00 and gave the stock an “outperform” rating in a research note on Friday, October 18th. Stifel Nicolaus lifted their target price on Intuitive Surgical from $525.00 to $610.00 and gave the company a “buy” rating in a research note on Thursday, December 5th. Evercore ISI restated a “cautious” rating on shares of Intuitive Surgical in a report on Friday, October 18th. Truist Financial increased their target price on Intuitive Surgical from $570.00 to $640.00 and gave the company a “buy” rating in a research report on Wednesday, December 18th. Finally, Piper Sandler restated an “overweight” rating and issued a $538.00 target price (up from $495.00) on shares of Intuitive Surgical in a report on Friday, October 18th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and fifteen have issued a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $554.17.

Insider Buying and Selling at Intuitive Surgical

In other Intuitive Surgical news, EVP Brian Edward Miller sold 2,553 shares of the stock in a transaction dated Tuesday, October 22nd. The stock was sold at an average price of $515.00, for a total value of $1,314,795.00. Following the completion of the sale, the executive vice president now directly owns 7,066 shares in the company, valued at approximately $3,638,990. This trade represents a 26.54 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Gary S. Guthart sold 18,151 shares of the business’s stock in a transaction dated Wednesday, October 30th. The stock was sold at an average price of $511.63, for a total value of $9,286,596.13. Following the sale, the chief executive officer now owns 24,219 shares in the company, valued at $12,391,166.97. The trade was a 42.84 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 48,190 shares of company stock worth $25,012,927 over the last three months. Corporate insiders own 0.80% of the company’s stock.

Intuitive Surgical Price Performance

Shares of NASDAQ ISRG opened at $584.08 on Friday. Intuitive Surgical, Inc. has a 1-year low of $355.17 and a 1-year high of $585.50. The business has a fifty day moving average price of $538.34 and a 200 day moving average price of $497.08. The stock has a market capitalization of $208.04 billion, a P/E ratio of 93.90, a price-to-earnings-growth ratio of 4.66 and a beta of 1.39.

Intuitive Surgical (NASDAQ:ISRG) last released its quarterly earnings results on Thursday, October 17th. The medical equipment provider reported $1.56 EPS for the quarter, beating the consensus estimate of $1.24 by $0.32. The business had revenue of $2.04 billion during the quarter, compared to analyst estimates of $2.01 billion. Intuitive Surgical had a net margin of 28.51% and a return on equity of 13.41%. As a group, equities research analysts anticipate that Intuitive Surgical, Inc. will post 5.45 earnings per share for the current fiscal year.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.